Latest stories on EWTX
William Blair initiates Edgewise Therapeutics stock with outperform rating
Investing.com Analyst Ratings63 · neutralanalyst
Edgewise Therapeutics initiated with an Outperform at William Blair
The Fly63 · neutralanalyst
Edgewise’s EQUINOX-HFpEF Trial: A Fresh Catalyst in the Heart Failure Pipeline
TipRanks61 · neutralproduct/pr
Edgewise Therapeutics doses first patient in Phase 2 trial of EDG-15400
The Fly63 · neutralproduct/pr
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
PR Newswire63 · neutralproduct/pr
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire50 · neutralgeneral
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow
Seeking Alpha55 · neutralproduct/pr
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
PR Newswire63 · neutralproduct/pr
Edgewise Therapeutics options flow shows lopsided call activity
Investing.com Markets58 · neutralgeneral
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire50 · neutralgeneral
Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan
The Fly63 · neutralanalyst
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Seeking Alpha73 · bullishproduct/pr
Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
The Fly61 · neutralanalyst
Edgewise Therapeutics GAAP EPS of -$0.53
Seeking Alpha34 · bearishearnings
Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
PR Newswire73 · bullishearnings
8-K/A - Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
TipRanks52 · neutralgeneral
Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
PR Newswire62 · neutralm&a
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
PR Newswire63 · neutralm&a
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire50 · neutralgeneral
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
Yahoo Top57 · neutralanalyst